Custom Gene-Editing Therapies for Rare Diseases Could Win Faster Approvals Under FDA Draft Plan, Not Yet Final

The FDA’s draft guidance could streamline approval of gene-editing therapies tailored to individual mutations, while families and experts weigh safety, affordability, evidence requirements, and access challenges.